Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

April 4, 2019

Vital Therapies, Inc. Announces Stockholder Approval of Business Combination with Immunic AG
April 2, 2019

Immunic Therapeutics To Present At The Needham Healthcare Conference On April 10
March 27, 2019

Vital Therapies Reminds Stockholders to Vote For the Proposed Business Combination With Immunic AG

Of the Votes Received to Date, More than 98% are Voting in Favor of the Business Combination
March 25, 2019

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Vital Therapies Stockholders Vote “FOR” the Proposed Business Transaction With Immunic AG and All the Related Proposals
March 4, 2019

Vital Therapies Announces 2018 Financial Results
February 28, 2019

Immunic Therapeutics to Participate in Investor and Medical Conferences in March
February 26, 2019

Immunic Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of IMU-838, an Oral Therapy for Patients with Relapsing-Remitting Multiple Sclerosis
February 6, 2019

Immunic Therapeutics to Present at the BIO CEO & Investor Conference on February 11
January 7, 2019

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets
November 5, 2018

Immunic enters into a global option and license agreement with Daiichi Sankyo

Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease

Show per page